Rosiglitazone is a drug FDA approved for the treatment of type 2 diabetes mellitus. It belongs to the family called thiazolidinediones. It is capable of lowering the glucose levels by improving target cell response to insulin without increasing the stimulation and release of insulin by the pancreatic beta cells.
Rosiglitazone is a potent and highly selective agonist for the nuclear receptor peroxisome proliferator – activated receptor – gamma (PPAR-gamma). PPAR-gamma increases the transcription of certain insulin – sensitive genes, thereby improving insulin sensitivity.
Rosiglitazone is a potent and highly selective agonist for the nuclear receptor peroxisome proliferator – activated receptor – gamma (PPAR-gamma). PPAR-gamma increases the transcription of certain insulin – sensitive genes, thereby improving insulin sensitivity.
© 2025[current_year] The Doctors Platform. All Right Reserved.
© 2025 The Doctors Platform. All Right Reserved.
